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HBV vaccination coverage
among health-care
workers
De Schryver et al.
1 were rightly con-
cerned by the HBV vaccination coverage
among health-care workers (HCWs) in
11 countries of the European Union
where it is mandatory. France is among
those where no data are available and
some information about a very specific
situation must be disclosed.
On 3 November 2010, the members of
parliament voted a E100000 individual
compensation to 20 firefighters for ad-
verse effects (multiple sclerosis) due to
hepatitis B vaccination (mandatory too
because they actively participate to emer-
gency care).
This is sadly in the line of a major
pre-publication release campaign of a
research conducted with funding from
several major national bodies (including
AFSSAPS, the French FDA) which stated
in 2008 that ‘Engerix B vaccine appears
to increase the risk of CNS inflammatory
demyelination in childhood’.
2
Accordingly, 30 years after Philippe
Maupas’ publication in the Lancet of
the first clinical trial of vaccination
against hepatitis B in humans, per-
formed at Tours (France), in 2006,
in France, the percentage of 1-year-olds
immunized with three doses of
hepatitis B was 29% (vs. 86% in
Germany, a comparable country), lower
than in most of the very poor countries
in the world.
2,3
The Institut National de Veille
Sanitaire (INVS, the French Center for
Diseases Control) has recently (July
2010) reported a slight increase in the
percentage of 1-year-olds who are immu-
nized (BEH, 27 July 2010, p. 330).
However, the population was selected
for its compliance to follow-up consult-
ations and those who only got one shot of
the vaccine were considered to be fully
immunized.
Meanwhile, the National Cancer
Institute refuses to present data on the
evolution of hepatocellular cancer mor-
tality stating that the data have a too low
quality.
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Influenza surveillance in
Europe
In the viewpoint entitled ‘Potential for
greater coherence in EUROPEAN influ-
enza surveillance’ and published in your
last edition, EJPH 2010, 20(5):488–9,
Johnson H et al. analysed the publically
available data on influenza surveillance
reported in the European Influenza
Surveillance Network (EISN, formerly
European Influenza Surveillance
Scheme (EISS)) managed by the
European Centre for Disease Prevention
and Control (ECDC) and in the EuroFlu
managed by WHO – Europe. The former
agency reports data from 27 European
Union (EU) countries and two
European Economic Area (EEA) coun-
tries, and the latter collects data from
53 countries from the WHO European
Region (that include the former coun-
tries). During the period 2009–10, the
authors correctly observed that 7% of
the data from the countries reporting
in both bulletins were contradictory.
The authors suggested some hypotheses
to explain these discrepancies, from dif-
ferent data uploaded to different nation-
al contact points for reporting in some
countries. Both ECDC and WHO –
EURO have been aware of such differ-
ences. While small, they are being ad-
dressed in our ongoing coordination
for quality assurance. An important im-
provement that should lead to a
decreased number of these discrepancies
is the new reporting technical solution
introduced by European Centre for
Disease Prevention and Control
(EDCD) and WHO – Europe. As of
January 2010 the reporting for the 29
EU/EEA countries is now synchronized
and uses a single data entry point for
both platforms. In addition, as a further
step towards coordinated surveillance of
influenza at the European level, in May
2011, ECDC and WHO – Europe will for
the first time organize a joint annual
meeting of their influenza surveillance
network members where the influenza
surveillance activities, including the val-
idity and quality of the data and the ana-
lyses will be discussed. Beginning with
the 2010–11 influenza season WHO –
EURO and ECDC are now jointly re-
viewing weekly bulletins from both agen-
cies, and we are writing joint guidance
on human influenza surveillance. Taken
together, these activities should improve
the quality of the influenza data in
Europe in the future.
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